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A Salmonella specific bacteriophage Felix O1 (Myoviridae) was microencapsulated in a pH responsive
polymer formulation. The formulation incorporated a pH responsive methacrylic acid copolymer
Eudragit® S100 (10% (w/v)) with the addition of the biopolymer sodium alginate, the composition of
which was varied in the range (0.5% (w/v)e2% (w/v)). The microencapsulation process employed
commercially available microfluidic droplet generation devices. We have used readily available low cost
microfluidic chips instead of bespoke in-house fabricated glass capillary devices which are accessible
only in specialist research facilities. We show that these co-flow microfluidic devices can easily be used
to prepare phage encapsulated microparticles making them suitable for use by both the phage research
community and industry in order to evaluate and optimise phage compatible formulations for micro-
encapsulation. A novelty of the work reported here is that the size of the generated monodispersed
droplets could be precisely controlled in the range 50 mme200 mm by varying the flow rates of the
dispersed and continuous phases. Consequently, alginate concentration and microparticle size were
shown to influence the phage release profile and the degree of acid protection afforded to phages upon
exposure to simulated gastric fluid (SGF). Bigger microparticles (~100 mm) showed better acid protection
compared with smaller beads (~50 mm) made from the same formulation. Increasing the alginate
composition resulted in improved acid protection of phages for similar particle sizes. The high viscosity
formulations containing higher amounts of alginate (e.g. 2% (w/v)) negatively affected ease of droplet
generation in the microfluidic device thereby posing a limitation in terms of process scale-up. Felix O1
encapsulated in the formulation containing 10% (w/v) ES100 and 1% (w/v) alginate showed excellent
protection upon exposure of the gelled microparticles to SGF (pH 1 for 2 h) without the use of any
antacids in the encapsulation matrix. Encapsulated phages previously exposed to SGF (pH 1 for 2 h) were
released at elevated pH in simulated intestinal fluid (SIF) and were shown to arrest bacterial growth in
the log growth phase. We have therefore demonstrated the microencapsulation of phages using readily
available microfluidic chips to produce solid dosage microcapsule forms with a rapid pH triggered release
profile suitable for targeted delivery and controlled release in the gastrointestinal tract.
© 2018 The Author(s). Published by Elsevier Masson SAS on behalf of Institut Pasteur. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
The emergence of antibiotic resistant bacteria is a serious
global threat to human health. Common enteric bacterial path-
ogens have become progressively more resistant to standard
antibiotics [1,2]. Government Health Departments are increas-
ingly banning general antibiotic use in food animal production
e.g. see EU directive on additives for use in animal nutrition [3].evier Masson SAS on behalf of IIn addition to treating infections in humans, a safe and low cost
biocontrol strategy to reduce pathogen carriage in livestock and
poultry is also needed. The development pipeline for new classes
of novel antibiotics is not looking promising [4]. There are
frequent calls from government health agencies around the
world to explore alternative treatment options [5]. Lytic bacte-
riophages (phages) are viruses that infect and kill bacteria, and
they represent a promising approach to targeting bacterial in-
fections in a treatment known as phage therapy [6e9]. The
specificity of bacteriophages and their potential role in main-
taining healthy gut microbiota makes them an alternative to
employing antibiotics [10]. The use of phage therapy is anstitut Pasteur. This is an open access article under the CC BY license (http://
G.K. Vinner, D.J. Malik / Research in Microbiology 169 (2018) 522e530 523particularly promising alternative to broad spectrum antibiotic
treatment for acute enteric infections because typically in such
infections intestinal concentration of infecting bacteria is high,
the causative agent and strain may be suitably diagnosed using
rapid diagnostic tools, and application of phage therapy with a
sufficiently high initial phage dose would promote rapid in situ
phage multiplication and decrease in the host bacterial popula-
tion [2,11e13]. Enteric infections worldwide are typically caused
by pathogens such as Clostridium difficile, Escherichia coli, Sal-
monella spp, Vibrio cholera [14]. Any such pathogen is potentially
a target for phage therapy however, there are major barriers to be
overcome in terms of understanding the dynamics of the inter-
action between phage and bacteria in the gut environment, and
in terms of the logistics of delivering a stable defined product to
the infection site [15].
It is estimated that Salmonella alone accounts for 1.2 million
foodborne illnesses in the United States, with 23,000 hospital-
isations and 450 deaths costing an estimated 365 million dollars in
medical costs each year [16]. Increasing centralisation and indus-
trialisation of food supply enhances the probability of distribution
of these hardy organisms. Antimicrobial resistance to ‘first-line’
drugs is increasingly common among Salmonellaworldwide [17]. In
animals, decolonisation of the gastrointestinal tract from Salmo-
nella may be beneficial for biocontrol to reduce dissemination of
harmful bacteria through the food chain e.g. lairage associated
Salmonella transmission in pigs [18]. Ensuring delivery and subse-
quent release of a precise high dose of phages to the site of infection
in the gastrointestinal tract remains an important challenge to
ensure that phage therapy develops its full potential as a thera-
peutic or prophylactic antimicrobial agent [19]. Encapsulation may
help protect phages from loss of activity during manufacturing and
storage and during transit through the stomach en route further
downstream in the gastrointestinal tract. Encapsulation in solid
dosage forms e.g. microcapsules may also permit easy oral dose
application allowing phage administration through feed instead of
administration via oral gavage.
When free phages are delivered orally for phage therapy or for
modulating microbiota, there is likely to be variable but significant
losses of phage titre by the time phages reach the intended infec-
tion site [20]. Oral application of phages exposes them to stomach
acidity, digestive tract contents (e.g. enzymes such as pepsin and
pancreatin) which can inactivate phages [21]. A recent in vivo study
in chickens (phage were added to animal feed) using alginate
microencapsulated Salmonella Felix O1 phages showed a significant
reduction in levels of phage titre (3 log reduction compared to the
dose given) found in the gastrointestinal tract [22]. Potential
reduction in phage titres due to inactivation attributed to stomach
acidity may in part have been responsible for failure of a recent
clinical trial treating acute bacterial diarrhoea symptoms in chil-
dren using phage therapy [15]. Acidic conditions encountered in
the stomach and the presence of bile and digestive enzymes and
other proteases in the intestinal tract and stomach may inactivate
unformulated phages [23e25]. Use of antacids may increase the
risk of gastroenteritis and its use was not permitted in a recent
clinical trial [15]. In a separate study, mice were given an oral dose
(T4 coliphages in drinking water) of 109 PFU/g gut contents which
resulted in a 1000-fold lower titre, indicating a sizable loss in phage
activity [21]. Therefore, there are clear drivers to protect phages
against adverse gastrointestinal conditions by encapsulating them
and to control their targeted release at the site of infection e.g. in
the lower gastrointestinal tract (GIT) i.e. ileum, cecum and colon for
Salmonella and other enteric infections [24e26].
Previous phage encapsulation strategies have used basic
homogeniser and extrusion techniques and have employed for-
mulations that are gentle in terms of avoiding use of organicsolvents that would inactivate phages [24,25,27e29]. These studies
have shown modest protection of phages when the capsules were
exposed to simulated gastric fluid at pH values in the range 2e2.5,
for up to 2 h exposure duration. We recently showed for the first
time the potential of microfluidic encapsulation for a C. difficile
specific phage using an in-house developed microfluidic device
[30]. In-house built microfluidic droplet generation devices are
highly versatile however they require a high level of fabrication
expertise including access to specialist micro-forging equipment,
the devices are fragile, difficult to handle, prone at times to leakages
and ingress of air bubbles causing contamination and production
issues especially for processing of biological materials. The aim of
this study was to use commercially available low cost glass
microfluidic droplet generation systems to microencapsulate
phage. Additionally, in our recent publication the phage titre for the
encapsulated C. difficile specific phage was rather low
(107 PFU ml1), the formulation was not optimised and acid pro-
tection was limited to pH 2. The objectives here were to precisely
control microparticle size and hence investigate the effect of par-
ticle size and formulation parameters (alginate composition) in
order to prepare pH responsive microparticles that were able to
withstand significantly low gastric acidity (as low as pH 1 for 2 h)
without appreciable loss in phage activity at high encapsulated
phage titres.2. Materials and methods
2.1. Chemical reagents
A methyl methacrylate co-methacrylic acid copolymer Eudra-
git® S100 was purchased from Evonik Germany. Miglyol 840, a
propylene glycol diester of caprylic/capric acid, was purchased from
Sasol Germany and used as carrier oil for the continuous phase.
Polyglycerol polyricinoleate (PGPR) an oil soluble surfactant was
purchased from Abitek USA. Para-toluenesulfonic acid and sodium
chloride were purchased from Fisher Scientific, UK. Sorensen's
buffer 0.2 M was used as a dissolution media for the microparticles
and was prepared by mixing sodium phosphate (NaH2PO4) with
sodium phosphate dibasic (Na2HPO4) (for pH 7) (Fisher Scientific
UK). Alginate was purchased from Sigma Aldrich, UK.2.2. Salmonella strain and bacteriophage Felix O1
Salmonella enterica ATCC19585 was purchased from LGC stan-
dards, EU. Phage Felix O1 was kindly donated by Dr Cath Rees,
University of Nottingham, UK [31]. S. enterica strain was used to
propagate and enumerate Felix O1. Brain heart infusion broth and
agar (Oxoid UK.) were used for all bacterial work. A single colony
from a streaked overnight culture on a BHI agar plate was used to
inoculate fresh BHI broth and left shaking overnight at 37 C. The
culture was diluted and regrown to log phase at 0.2 O.D. (550 nm)
for all phage work.
Felix O1 was propagated by infecting a log phase culture of
S. enterica at MOI 0.01. Once the culture had cleared the lysate was
centrifuged at 2000 g for 15 min at 4 C and filtered using a 0.2 mm
pore size filter (Millipore, USA). All phage stocks were stored at 4 C
until further use.
To titre the phage stocks,10 ml of phage stockwas serially diluted
(10-fold) to 108 in 90 ml of BHI broth. This was spotted in triplicate
on a double layer agar plate containing 10 ml of overnight culture of
host, S. enterica. The plate was dried near a flame and then incu-
bated overnight at 37 C. The following day plaques were counted
to determine the phage titre and expressed as plaque forming units
(PFU) per ml.
Fig. 1. Schematic of experimental setup used to produce water-in-oil (W/O)
emulsions for phage microencapsulation. Microscope stage with mounted micro-
fluidic chip connected to two high precision microfluidic syringe pumps suppling the
aqueous dispersed phase (containing phages suspended in the polymer formulation)
and the oil (continuous phase) respectively. High speed camera connected via com-
puter to microscope for high frame rate visualisation of droplet generation and in situ
control of droplet size through controlling of the flow parameters.
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in formulations at different temperatures
Simulated gastric fluid (SGF) was used to test phage sensitivity
to different pH values. SGF was prepared using the following
formulation: 0.2 M NaCl with pepsin at 3.2 mg/ml for solutions of
pH 1, 2, 2.5 and 3. For simulated intestinal fluid (SIF), pH solutions 4
to 7, 0.2 M Sorensen's buffer was used with the addition of 10 mg/
ml pancreatin. Time points were taken at 0 min, 30 min,1 h, 3 h, 6 h
and 24 h. For pH 2 and 2.5 exposure time points were also taken
every minute for the first 10 min. 10 ml was removed at each time
point and serially diluted 10-fold to 108 as described above. The
samples were spotted in triplicate on a lawn of the host bacteria
introduced via the double layer agar method. The plates were
incubated at 37 C overnight and checked for PFU the following day.
Eudragit S100 (ES100) was dissolved in deionised water dH2O
by dripping 4 M NaOH until the solution was clear. The solution pH
was adjusted to pH 7 using 0.1 M HCl. To this solution different
concentrations (0.5% (w/v) designated D3, 1% (w/v) designated D2,
2% (w/v) designated D1) of alginate was added and dissolved by
stirring at 60 C overnight in 50 ml Duran bottles equipped with a
magnetic stirrer to aid mixing (Table 1). The polymer solutions
were left to cool before phage stock was added. Felix O1 stock was
concentrated by centrifuging in Amicon tubes (Millipore, UK) with
a 100 kDa filter for 15min and 2000 g. This concentrated phagewas
added to the dispersed aqueous phase solution to make the final
concentration of phage of ~108-1010 PFUml1. Phage stability in the
polymer solutions was measured at room temperature ~20 C
stored over five days and stored at 4 C for up to a week.
2.4. Felix O1 encapsulation using microfluidic droplet generation
system
The continuous oil phase was made of a 50:50 mixture of
Miglyol 840 and Castor oil (Elf Foods, Loughborough, UK), with 5%
(w/v) PGPR. The emulsion was collected in acidified oil, consisting
of 0.05 M p-toluenesulfonic acid in Miglyol with 5% (w/v) PGPR.
Eudragit-alginate droplets were prepared by using a hydro-
phobic quartz droplet junction chip with an etch depth of 190 mm
purchased from Dolomite, UK (Fig. 1). The dispersed aqueous phase
(phages in polymer formulations D1-D3) was introduced through
the inner/middle channel and the continuous phase from the two
outer channels. The phases were pumped via 10 ml syringes (BD
Plastipak, UK) mounted on syringe pumps (Harvard Apparatus,
UK). The two phases were delivered and collected through medical
delivery tubes (0.86 mm inner diameter and 1.52 mm outer
diameter, Smiths Medical International Limited, UK). As the two
phases met at the interface, the oil phase causes the aqueous phase
to pinch and form droplets. The flow rates for all formulations were
kept constant and maintained to keep the dripping regime
(Table 1). The droplet formation was observed via a high-speed
camera (Micro C110 Phantom Ametek, UK), connected to an
inverted microscope (Nikon Eclipse E200) using x 4 magnification
objective lens. The camera was connected via computer allowing
recording of the droplet formation at around 3000 frames perTable 1
Compositions of formulations and operating parameters for microfluidic device used to
Formulation ID D1 D2
Composition 10% (w/v) ES100
2% (w/v) Alginate
~109 PFU/ml
10
1%
~1
Dispersed phase flow rate, Qd/ml h1 50 25
Continuous phase flow rate, Qc/ml h1 1000 10second. The forming droplets were collected in acidified oil and
allowed to crosslink for a minimum of 2 h.
The acidified oil was removed by pipetting off the oil layer after
gentle centrifugation at 300 g for 5 min to settle the acidified mi-
croparticles. An excess of 0.1 M CaCl2 was added to the micropar-
ticles to crosslink the alginate for 1 h. Microparticles were collected
by centrifuging at 2000 g for 5 min and removing the CaCl2 solution
using a pipette. The gelled particles were stored hydrated at 4 C.
The drop and particle size were analysed using the Image J
program (National Institute of Health, Washington, U.S.) by
counting 10 drops or particles per sample. The particle sizes for
gelled microcapsules were measured using Coulter LS series 130
(Beckman Coulter Inc.), employing a Fraunhofer optical model for
data regression.
2.5. Scanning electron microscope (SEM)
Gelled particles were frozen on filter paper (0.2 mm pore size,
Millipore Ltd. UK) at 20 C overnight. The particles were freeze
dried (VirTis Wizard 2.0) for 24 h at 50 Pa pressure and 20 C. The
particles were put on viewing stubs using double sided carbon tape,
sputter coated with gold and viewed using a table top SEM (Hitachi
TM3030 Microscope).
2.6. Encapsulated phage release in SGF and SIF
100 mg of Felix 01 encapsulated particles (approximate) were
suspended in 10 ml prewarmed simulated intestinal fluid (SIF)
containing 10 mg/ml pancreatin in 0.2 M Sorensen's buffer at pH 7
(Sigma Aldrich, UK). All dissolution experiments were carried out at
37 C with shaking. For acid exposure to pH 1, 2, 2.5 and 3, 0.1 g
microparticles were suspended in 10 ml prewarmed simulated
gastric fluid (SGF) containing 3.2 mg/ml pepsin in 0.2 M NaCl at pH
2 (Sigma Aldrich, UK). After 2 h exposure to SGF at each pH, the
particles were centrifuged at 2000 g for 10 min, SGF removed andprepare emulsion droplets.
(s) D2(b) D3
% (w/v) ES100
(w/v) Alginate
09 PFU/ml
10% (w/v) ES100
1% (w/v) Alginate
~109 PFU/ml
10% (w/v) ES100
0.5% (w/v) Alginate
~109 PFU/ml
100 50
00 1000 500
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phage release. Phage release was monitored over 4 h, by taking
samples to enumerate phage release kinetics at hourly time points.
To do this, plaque assays were performed as described previously
by taking 10 ml samples, serially diluting and spotting on a bacterial
lawn using double overlay agar method. The plates were counted
the following day for plaques.
2.7. Encapsulated phage Salmonella killing
Salmonellawas cultured from a single colonywith a starting O.D.
(550 nm) of <0.001, shaking at 37 C overnight. 60 ul of overnight
culture was added to 60 ml of BHI. 2 ml of this starter culture was
added to 24 well tissue culture plates. Approximately 0.2 g of mi-
croparticles were added to multiple wells (for hourly time points)
to evaluate in vitro phage release, amplification and arresting of
bacterial growth. Microparticles used were either virgin or previ-
ously exposed to pH 1 for an exposure period of 2 h. At hourly in-
tervals 1 ml aliquots were withdrawn and the O.D. measured of the
controls (bacteria only), pH 1 exposed particles and non-pH 1
exposed particles. An additional 1 ml aliquot per well was trans-
ferred to an Eppendorf tube for each sample and centrifuged at
2000 g for 3 min for plaque assays. 10 ml was removed from the
supernatant to enumerate for phage using the double-layer agar
method as described previously. The pellet was separated and re-
suspended in fresh BHI broth, this was serially diluted and plated
on BHI agar plate to enumerate residual bacteria concentration. The
control was also serially diluted and plated to determine the bac-
teria concentration. The plates were incubated overnight at 37 C
and checked for plaques and colonies the following day. The results
were presented as the mean of three repeats.
2.8. Statistical analysis
Statistical analysis was carried out using the statistical software
Minitab 18. 2-Sample t tests were done to calculate 95% confidence
intervals and to carry out hypothesis tests of the difference be-
tween two population means.Fig. 2. Production of pH responsive microparticles using a microfluidic droplet generat
droplet size. (a) in situ imaging showing generation of small droplets in the microfluidic chip
collected small droplets with formulation D2(s) (mean drop size 73 mm ± 11 mm); (d) collec
small droplets with formulation D1 (mean drop size 64 mm ± 12 mm); (f) collected big drople
of gelled microparticles (after TSA exposure and CaCl2 crosslinking) using formulation D2(s) a
using formulation D2(b).3. Results
3.1. Production of phage encapsulated ES100-alginate
microparticles
Highly monodispersed droplets were produced for 0.5% (w/v)
(formulation D3, viscosity, 25 cP) and 1% (w/v) (formulation D2,
viscosity 64 cP) alginate compositions (all solutions contained 10%
(w/v) ES100). Droplet generation was stable for formulations D2
and D3 over extended periods with drops collected for several days
without interruption. Formulations with alginate compositions
higher than 1% (w/v) were highly viscous, (2% (w/v) alginate so-
lution having a measured viscosity of 574 cP) and this resulted in
difficulties in maintaining uniformity of droplet generation for
prolonged periods due to flow instabilities causing disruption in
droplet generation and observation of jetting phenomena dis-
cussed elsewhere [30]. Stable production of uniform droplets
required at-line optimisation of the hydrodynamic conditions.
Microfluidic droplet generation devices can be controlled in situ by
direct microscopic observation. Hydrodynamic conditions were
optimised for each formulation in real-time by adjusting fluid flow
rates during each experiment until uniform droplets were pro-
duced (Table 1). Thereafter only small changes to these values were
needed to achieve droplets of similar sizes ensuring batch-to-batch
uniformity of droplets (data not shown).
To enable better control of the droplet generation process and in
order to reliably produce droplets with low polydispersity, the
‘dripping regime’ worked best. Here, the droplets were formed
closer to the orifice of the collection capillary (Fig. 2a and b)
because the interfacial tension forces dominated over the inertia of
the dispersed phase and the viscous stress forces from the
continuous phase. Droplet formation began as the dispersed phase
entered into microfluidic flow focusing zone (Fig. 2a and b). The
dispersed phase did not come into contact with the capillary wall
due to repulsion from the hydrophobic surface of the collection
capillary wall which was designed to resist wetting by the aqueous
phase. The continuous phase forced the dispersed phase to elon-
gate axially (Fig. 2b), collapsing the dispersed phase and producingion system. At-line optimisation of hydrodynamic conditions allowed control over the
using formulation D2(s) and (b) formation of big droplets using formulation D2(b); (c)
ted big droplets with formulation D2(b) (mean drop size 190 mm ± 5 mm); (e) collected
ts with formulation D3 (mean drop size 164 mm ± 19 mm); (g) particle size distributions
nd D2(b); (h) scanning electron micrograph of freeze dried big microparticles prepared
Fig. 3. Felix 01 stability upon exposure to solutions of different pH and in for-
mulations D1-D3 upon storage. (a) Phage suspensions were exposed to 0.2 M NaCl
with pH adjusted in the range pH 2 e pH 7. Phages were exposed for different time
periods at each controlled pH. Time point 0 h refers to exposure for ~1 min. (b) Phages
stored in formulations D1-D3 refrigerated at 4 C, dark grey bars (day 0), light grey bars
(day 7). (c) Phages stored in formulation D2 stored at room temperature at ~20 C.
Error bars are 95% confidence intervals (n ¼ 3). * indicates significance (p < 0.05) using
a 2-sample t-test as compared with sample at pH 7 exposed for the same time period
in (a) and Day 0 in (c).
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further, the neck thinned into a thread, eventually breaking the
dispersed phase and releasing the droplet. Following retraction, the
process restarted with the dispersed phase protruding at the orifice
of the collection capillary. In this dripping regime, the formation of
one droplet took ~95 ms, thus ~10 droplets were formed each
second and subsequent droplets were produced at the same posi-
tion as the previous droplets. The balance between the drag force
and interfacial tension and negligible shear in the collection
capillary after drop formation resulted in uniform droplets.
The ability to readily change the droplet size is an important
feature of microfluidic droplet generation systems enabling control
over the final microparticle size. Droplet generation in the dripping
regime was optimised over a range of flow rates for alginate for-
mulations of differing viscosities thereby enabling control of the
droplet size whilst maintaining a reasonably high degree of the size
uniformity (Fig. 2 cef). This was done in real-time whilst observing
(using the microscope camera) the change in the resulting droplet
size. Increasing the flow rate of the inner phase relative to the outer
phase resulted in an increased size of the droplets e.g. for formu-
lation D2 (Fig. 2c and d, Table 1).
Droplet formation in the microfluidic droplet generation chip
was followed by curing in acidified oil, removal of acidified miglyol
and subsequent gelling of alginate in 0.1 M CaCl2. This resulted in
distinct gelled solid microspheres (Fig. 2h). The gelling process
resulted in significant shrinkage in the size of the final micropar-
ticles measured using a Coulter particle size analyser (Fig. 2g) and
through visualization of freeze dried particles using SEM imaging
(Fig. 2h).
3.2. Effect of acid exposure on Felix O1 viability and phage stability
upon storage in formulations at different temperatures
The effect of acidic pH on Felix O1 phage viability was tested.
Phages were suspended in 0.2 M sodium chloride solutions with
varying pH. The phages lost nearly all activity after 10 min of
exposure to pH 2 and lost activity progressively upon exposure to
pH 2.5 over a period of 6 h (Fig. 3a). Phage viability was significantly
improved when the solution pH was above pH 3.
Phage Felix O1 was found to be stable and retain titre upon
formulation in 10% (w/v) ES100 containing between 0.5% (w/v) to
2% (w/v) alginate (formulations D1-D3) upon storage under
refrigerated conditions at 4 C for up to 1 week (Fig. 3b) and over
several days in syringes mounted in microfluidic pumps used
during droplet generation at room temperature (data shown for
formulation D2, Fig. 3c).
3.3. Microencapsulated phage exposure to simulated gastric fluid
(SGF) and phage release in simulated intestinal fluid (SIF)
Having a controlled flow rate of polymer solution containing
phages at a known phage titre allowed calculation of the theoretical
yield of phages recovered in the final collected gelled microparti-
cles. Near 100% (typically > 95%) encapsulation of phages was
observed following the entire encapsulation process. Gelled mi-
croparticles prepared using formulations D2(s) and D2(b) were
added to shaking solutions containing SGF with pH adjusted to pH
1, pH 2, pH 2.5 and pH 3 and microparticles were exposed for 2 h
followed by centrifugation and separation of the microparticles
from SGF. Microparticles were subsequently exposed to SIF and the
kinetics of phage release was measured. Time point 0 h refers to
phages released within the first 10 min upon exposure to SIF. Small
1% (w/v) alginatemicrobeads (D2(s), mean size 50 mm)were able to
protect encapsulated Felix O1 phages to SGF with pH as low as pH
2.5 (Fig. 4a). However, lowering the pH further resulted in titre dropfrom 1  109 PFU ml1 to 4  107 PFU ml1 (at pH 2) and complete
loss of phage titre upon exposure to pH 1. No phages were recov-
ered for small microparticles prepared using formulation D2(s)
exposed to SGF at pH 1. Using formulation D2(b) and increasing the
Fig. 4. Protection of encapsulated Felix O1 bacteriophage from SGF and release of
phages upon exposure to SIF. (a) acid protection and phage release kinetics for small
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improvement in phage viability with no measured loss in phage
titre for microparticles exposed to pH 1 (Fig. 4b). The release profile
also changed from burst release for small microbeads to slow
release for the larger microbeads with around 20% of encapsulated
phage dose released after 1 h and near complete release after 2 h of
exposure to SIF. Small microbeads prepared using formulation D1
(containing 2% (w/v) alginate) significantly improved phage acid
protection compared with particles prepared using formulation
D2(s) with phages surviving exposure albeit with titre reduction
upon exposure to SGF at pH 1 (Fig. 4c). For larger microbeads
lowering the alginate composition (formulation D3) reduced acid
protection with 0.5% (w/v) alginate samples showing acid protec-
tion down to pH 3 with significant drop in phage titres at pH 2.5
and no acid protection at pH values at or below pH 2 (Fig. 4d).
3.4. Microencapsulated phage release and Salmonella killing
Large 1% (w/v) alginate microbeads (D2(b)) pre-exposed to SGF
(pH 1) rapidly released phage with the phage titre rising to
~1  106 PFU ml1 shortly after addition (Fig. 5 c). Optical density
measurements showed a clear deviation in Salmonella growth in
cultures at time point 3 h post microparticle addition for small and
large microparticles (particles had previously been exposed to SGF
at pH 1 for 2 h, Fig. 5 a). For big particles (D2(b)) the CFU counts
dropped sharply after 3 h with concomitant amplification of phage
titres (Fig. 5 b, c). Exposure to SGF at pH 1 resulted in considerably
lower phage titres in the small 1% (w/v) alginate microparticles
(D2(s)), therefore phage release from the small microbeads resulted
in much lower phage titre (1  103 PFU ml1). This resulted in a
significant delay in both Salmonella CFU reduction (~4 h) and sub-
sequent phage amplification (Fig. 5 b, c). 4 h post microparticle
addition both sets of cultures had arrested Salmonella growth and
considerable phage amplification was noted with phage titre rising
to ~1 1010 PFUml1 however, the time taken to arrive at this level
differed significantly for the two 1% (w/v) alginate samples (D2(s)
and D2(b)) indicative of the effect of phage dose on phage-
bacterium population dynamics.
3.5. Storage stability of encapsulated phage
Large microparticles (prepared using formulation D2(b)) stored
over the course of 4 weeks under refrigerated conditions (at 4 C)
showed a modest drop in phage titre (Fig. 6). Phage titre dropped
from ~4  108 PFUml1 microparticle at week 0e1  108 PFUml1
microparticles after 1 week of storage. Thereafter, phage titre
remained stable up to week 4 (the extent for which measurements
were taken).
4. Discussion
Motivation for research into solid dosage forms for oral appli-
cation of phages is driven by the need to protect phages from the
harsh gastrointestinal tract environment. Phage mediated reduc-
tion of bacterial levels in vivo requires high titres of viable phages
delivered precisely at the site of infection that are able to target the
host and arrest bacterial growth [19]. Previous efforts targeting
Salmonella in the food chain have attributed poor phage stability in
the gastrointestinal tract for insufficient in vivo efficacy [18]. In vitro
phage stability experiments exposing phages to solutions ofmicroparticles, formulation D2(s); (b) acid protection and phage release kinetics for big
microparticles, formulation D2(b); (c) acid protection and phage release kinetics for
small microparticles, formulation D1; (d) acid protection and phage release kinetics for
big microparticles, formulation D3. Error bars are 95% confidence intervals (n ¼ 3).
Fig. 5. Dynamics of phage killing of S. enterica (serovar Typhimurium) bacteria
with microencapsulated Felix O1 bacteriophage. (a) Optical density curves showing
bacterial growth without (controls) and with the addition of microparticles D2(s) and
D2(b); (b) corresponding CFU data showing bacterial killing in the presence of added
microencapsulated phages (D2(s) and D2(b)) pre-exposed to simulated gastric fluid
(exposure period of 2 h at pH 1) prior to addition to salmonella bacterial cultures; (c)
Phage titre amplification in Salmonella cultures following phage release from micro-
encapsulated particles. Error bars are 95% confidence intervals (n ¼ 3).
Fig. 6. Storage stability of Felix O1 phage encapsulated in microparticles prepared
using formulation D2(b) (~100 mm beads) stored refrigerated at 4 C. Phage titre
was evaluated by exposing microparticles to simulated intestinal fluid (pH 7). * in-
dicates significance as compared with samples at day 0 (day of preparation) (p < 0.05)
using a 2-sample t-test. Error bars are 95% confidence intervals (n ¼ 3).
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vival and a prerequisite during formulation development prior to
testing in animal models [32]. Salmonella Felix O1 phages
(belonging to theMyoviridae family) were shown here to be highly
sensitive to acidic pH. Similar results have been reported previously
for phage Felix O1, other Salmonella phages as well as staphylo-
coccus aureus bacteriophage K (also a myovirus) and for E. coli
specific phages [24,26,27,33,34]. This loss of phage activity high-
lights the need to protect phages from the harsh acidic environ-
ment of the stomach if controlled doses of phages are to be reliablydelivered to treat salmonellosis in the infected gut. Phage Felix O1
titre was stable stored at 4 C in formulations of dissolved ES100
10% (w/v) containing variable alginate amounts over the range 0.5%
(w/v) e 2% (w/v). Microencapsulated Felix O1 formulated using 1%
(w/v) alginate in large 100 mmmicroparticles was shown to survive
2 h exposure to SGF at pH values as low as pH 1 without loss of
phage titre. Felix O1 microencapsulated in alginate beads has pre-
viously been shown to survive and amplify in the gastrointestinal
tract of pigs [18]. In vitro results reported here suggest that high
Salmonella phage titres could be delivered to the gastrointestinal
tract, subsequently released there using a pH trigger and should
remain viable thereafter. The pH of the colon can fall during bac-
terial infection to around or just below pH 7; in such a case, the
released phage should remain viable and capable of lysing the
infecting Salmonella bacteria present in the gut [35].
Alginate hydrogel pores tend to be in the 5e200 nm range
depending on the degree of crosslinking [36]. The porosity of the
alginate gel microparticles affects phage viability upon exposure to
the acidic stomach environment. A number of previous studies
have used alginate as the main encapsulating agent either on its
own or in combination with whey protein or chitosan to improve
acid stability [18,24e27,37e39]. Phages encapsulated in cross-
linked pure alginate microparticles were found to be susceptible to
acid damage following exposure to simulated gastric fluid
[24,27,40,41]. We have shown that microparticle size and alginate
composition were important in ensuring acid protection for
encapsulated phage. The pH responsive character of Eudragit®S100
resulted in phages readily released upon exposure to pH 7. The
combination of small microparticle size and pH responsive char-
acter of the microparticles resulted in rapid release of phagewithin
the first 2 h upon exposure to SIF at pH 7. Previous studies on
encapsulated phages in largemicroparticles (~1mm) have reported
slower sustained release kinetics for alginate encapsulated phages
however, acid protection was reported to be poor [24,26]. Faster
release from small alginate microparticles (mean size ~ 100 mm)
containing CaCO3 as antacid was recently reported [39]. However,
exposure of these microparticles to simulated gastric fluid (pH 2.8
for 60 min) resulted in between 2 log and 3 log reduction in Sal-
monella phage titres suggesting that even with the addition of
CaCO3, phages were highly susceptible to SGF. Particle size was
previously shown to be an important factor influencing phage
protection from SGF for acid permeable beads [38]. The acid
diffusion path length increases with particle size thereby affording
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We have shown that encapsulation of phages in composite
Eudragit®/alginate microparticles with different mean sizes
(50e100 mm) may permit control over the release rate. Small par-
ticles showed rapid burst release of phage cargowhilst larger beads
showed an initial burst and then slower sustained release over 2 h.
Hence control over the microparticle size may be used to manip-
ulate the release rate of phages in vivo.
A number of in vivo animal studies have shown dose dependent
phage therapy outcomes, with high doses of phages resulting in
better clinical results [42e45]. Accurate control over the phage
dose delivered at the site of infection and the timing of the delivery
are important considerations [15,19,46]. Using in vitro experiments,
we have shown that loss in phage titre upon acid exposure to SGF
may result in a significant delay in phage amplification. This delay
potentially could allow bacteria to attain much higher bacterial cell
numbers in an in vivo setting with adverse treatment outcomes.
Failure of a recently concluded phage therapy trial for the treatment
of E coli diarrhoea in children was attributed to the lack of in situ
phage amplification due to low host cell numbers which were
nevertheless susceptible to phages in the phage cocktail adminis-
tered [15]. Lack of phage formulation, no antacid administration
and subsequent drop in phage titres due to phage exposure to
stomach acidity may have been a factor in the consequent lack of in
situ phage amplification [15]. These issues may be addressed
through proper formulation development and microfluidic encap-
sulation of high phage titres for targeted delivery and controlled
release of phages at the site of infection coupled with a better
understanding of phage-bacterium population dynamics in vivo
[13,47]. These aspects have heretofore received little attention in
the published literature.
We have demonstrated here that even after exposure of phage
encapsulatedmicroparticles to simulated gastric fluid at pH 1 for 2 h,
the released phage dose was unaffected and corresponded to
~1  108 PFU g1. The dose was sufficient to prevent rapid bacterial
growth in vitro and resulted in rapid phage amplification from an
initial titre of 1  106 PFU ml1 to ~1  109 PFU ml1 within 3 h of
addition of microencapsulated phages. In small animal studies (e.g.
mice) typical dose via oral gavage is around 100 ml which would
allow dosing of around 0.1 g of microparticles containing around
~108 PFU or higher through phage stock concentration. Such a dose is
indeed typical of many animal studies in literature [19,42,48e52].
Bacterial killing by phages is dependent onphage particles adsorbing
to the target bacteria with killing rates affected by the in situ con-
centrations of both bacteria and phage [13,53,54]. It is known that in
an in vivo situation, phage clearance mechanisms rapidly reduce the
phage concentration in the absence of host bacteria [52]. We have
shown here that a high phage dose is quickly able to arrest the rise of
bacterial growth. Tanji et al. [55] showed similar results for E. coli
using an in vitro chemostat experimental system. However, if low
starting concentrations of bacteria are present, phage concentrations
in vivo may decay significantly due to host clearance mechanisms
and phages may be unable to amplify and achieve a sufficiently high
concentration to eradicate the infecting bacteria until the bacteria
have had time to grow bacterial numbers substantially [19]. If phages
are administered prophylactically too early prior to infection or at
the early onset of infection (when the bacteria concentration is low),
clearance of phages by the host immune system or by other mech-
anisms (e.g. dilution or shortening of intestinal transit times during
diarrhoea) may result in lowering of the in situ phage concentration
resulting in poor phage therapy outcomes [19]. Under such condi-
tions mucoadhesion of phages trapped in small microparticles and
slow sustained phage release may be a good strategy. Encapsulation
of phages and their slow controlled releasemay help in ensuring that
the in situ phage concentration remains at a therapeutically effectivelevel (over a realistic time period) allowing phages to amplify once
the bacterial concentration increases to levels sufficient for in situ
phage amplification [19]. The size of microparticles may play an
important role in ensuring phage delivery is minimally affected by
the conditions of the diseased state. Increased loss of fluid from the
colon due to symptoms such as diarrhoea result in observed short-
ened mean transit times. Dilution of phages due to the high fluid
environment may be a particular challenge. Larger particles (~mm
size range)may bemore prone to the influence of short transit times.
Smaller particles predisposed to non-specific mucoadhesion which
may aid in phage retention and sustained release over a significant
time period [56,57]. A recent study showed better phage retention
(for animals treated with alginate encapsulated phages versus those
treated with free phages) in the caecum of chickens and a significant
reduction in Salmonella colonisation [39]. This was attributed to the
mucoadhesiveness of the small alginate microparticles (~100 mm)
used for encapsulating phage.
The versatility of microfluidic encapsulation technologies
readily allows screening and optimisation of formulations for
phages. Microfluidic approaches may allow fabrication of complex
microcapsules for co-encapsulation and simultaneous or sequential
release of several different phages encapsulated in individually
optimised formulations [19]. A high level of product innovation
may be achieved through utilisation of a multitude of different
trigger strategies including light, temperature, pH, enzymes etc
[19]. Such strategies may allow phage biotechnology companies in
the future to generate value and protectable intellectual property.
5. Conclusions
We have demonstrated the controlled production of highly
uniform small composite microcapsules (using commercially
available microfluidic droplet generation chips) with mean size
50e100 mm composed of Eudragit® S100 and with varying alginate
amounts. Highly uniform microparticles were produced with low
polydispersity enabling control over phage loading, acid stability
upon exposure to SGF and their subsequent pH triggered release in
SIF. Phage encapsulation and subsequent release kinetics revealed
that microparticle size and alginate composition are factors
affecting the pH stability and release profile of encapsulated
phages. 100 mm beads prepared from 10% (w/v) ES100 and with 1%
(w/v) alginate afforded phages excellent pH protection upon
exposure to SGF (exposure for 2 h at pH 1) with no loss in phage
titre. The microparticles released all their phage cargo within 2 h
upon subsequent exposure to SIF making them suitable solid
dosage forms for gastrointestinal delivery of phages. We have also
demonstrated the storage stability of the encapsulated phages
under refrigerated conditions over a 4 week storage period.
Furthermore, we demonstrated the effect of acid stability and high
phage dose delivery on the attenuation of salmonella bacterial
growth upon release of encapsulated phages after exposure of the
microbeads to SGF at pH 1. Future work will investigate the spatial
and temporal delivery of encapsulated phages in a relevant small
animal model and the suitability of these solid dosage forms to
target Salmonella infections in vivo.
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